Legal status in the United States
Is Rapamycin legal?
Read at FDA, DEA and WADAPublished by PepVault
Rapamycin (sirolimus) is FDA-approved (Rapamune, first in 1999), is not a federally controlled substance, and is not named on WADA’s Prohibited List, as of November 19, 2026.
Rapamycin at a glance
| Check | Status, read Nov 19, 2026 |
|---|---|
| FDA approval | Approved (Rapamune, 1999) |
| Compounding | Not checked yet |
| DEA schedule | Not controlled |
| Sport (WADA) | Not named on the list |
FDA approval
Sirolimus, the drug name for rapamycin, is FDA-approved, first as Rapamune oral solution in 1999 and Rapamune tablets in 2000, to prevent organ rejection in people 13 and older receiving a kidney transplant and to treat lymphangioleiomyomatosis (LAM); generic sirolimus tablets are sold under later applications. Drugs@FDA also lists sirolimus as a gel (Hyftor), a cream (Scomara) and a powder for injection (Fyarro). Its use for longevity is off-label.
Rapamune (oral solution)
Approved for preventing organ rejection after a kidney transplant; lymphangioleiomyomatosis (LAM). NDA 021083, first approved September 15, 1999.
- Drugs@FDA: Rapamune, application 021083, U.S. Food and Drug Administration. Read .
- Sirolimus tablets prescribing information on DailyMed, National Library of Medicine (DailyMed). Read .
Rapamune (tablet)
Approved for preventing organ rejection after a kidney transplant; lymphangioleiomyomatosis (LAM). NDA 021110, first approved August 25, 2000.
- Drugs@FDA: Rapamune, application 021110, U.S. Food and Drug Administration. Read .
- Sirolimus tablets prescribing information on DailyMed, National Library of Medicine (DailyMed). Read .
- Drugs@FDA: Rapamune, application 021110, U.S. Food and Drug Administration. Read .
- Drugs@FDA data (openFDA): applications listing “SIROLIMUS” as an active ingredient, U.S. Food and Drug Administration. Read .

Compounding
Not checked yet. We could not settle this at its primary source on November 19, 2026, so the page leaves it out rather than guess.
DEA schedule
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
- 21 CFR Part 1308, Schedules of Controlled Substances (eCFR, up to date as of November 16, 2026), Electronic Code of Federal Regulations. Read .
- Controlled Substances, Alphabetical Order (dated November 17, 2026), Drug Enforcement Administration, Diversion Control Division. Read .
Sport (WADA)
WADA’s 2026 Prohibited List doesn’t name sirolimus or rapamycin, and it is an approved drug, so S0, the class for unapproved substances, doesn’t reach it.
- World Anti-Doping Code International Standard, Prohibited List 2026 (in effect from January 1, 2026), World Anti-Doping Agency. Read .
What this means and doesn’t
This page reports what the agencies’ own pages said about Rapamycin in the United States when we read them on November 19, 2026. These are records of regulators, not study evidence; for what the research shows, see the compound page.
It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ. Agencies change their lists, so each fact carries its date and a link to the page it came from.
Questions
Is Rapamycin FDA approved?
Sirolimus, the drug name for rapamycin, is FDA-approved, first as Rapamune oral solution in 1999 and Rapamune tablets in 2000, to prevent organ rejection in people 13 and older receiving a kidney transplant and to treat lymphangioleiomyomatosis (LAM); generic sirolimus tablets are sold under later applications. Drugs@FDA also lists sirolimus as a gel (Hyftor), a cream (Scomara) and a powder for injection (Fyarro). Its use for longevity is off-label.
Is Rapamycin a controlled substance?
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
Is Rapamycin banned in sport?
WADA’s 2026 Prohibited List doesn’t name sirolimus or rapamycin, and it is an approved drug, so S0, the class for unapproved substances, doesn’t reach it.